EGFR and Lung Cancer | American Lung Association
A favourable prognostic marker for EGFR mutant non-small cell lung cancer: immunohistochemical analysis of MUC5B | BMJ Open
EGFR and Lung Cancer | American Lung Association
Lung cancer - The Lancet
Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer | BMC Cancer | Full Text
Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study - The Lancet Digital Health
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors | Science Translational Medicine
Figures and data in Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer | eLife
Frontiers | EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer
Cancers | Free Full-Text | Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors | Anticancer Research
IJMS | Free Full-Text | Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis - ScienceDirect
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis - eBioMedicine
Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II: Molecular Therapy - Oncolytics
Targeted therapies in lung cancer and Biomarkers
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity - ScienceDirect
Cells | Free Full-Text | Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
Cancers | Free Full-Text | Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
Cancers | Free Full-Text | EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities | British Journal of Cancer
Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression | Scientific Reports
The biology of EGFR mutations in lung cancer. In normal cells, binding... | Download Scientific Diagram
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes | Nature Communications
Overexpression of BZW1 and EGFR is a strong poor prognosis marker for... | Download Scientific Diagram
